What changed
$NVS — WATCHLIST 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.5B | EPS $1.99 vs $2.07 🔴
💡 Consensus expects gradual recovery from the miss, but our analysis indicates upside is capped at ~6% with downside of ~3.6%, suggesting the stock is fairly valued and offers no variant view premium.
📉 Reward/risk: 1.8:1
🏢 Business Quality: 8/10 - Diversified pharma with strong pipeline and established franchises, but facing generic competition and pricing pressure.
📊 Valuation: fair - using P/E and reverse DCF, base case implies 15x forward earnings, in line with historical average and peers; no multiple expansion expected...
🔮 Catalyst: lack of near-term identifiable catalyst within 3-month window
💰 Entry: $153.38, stop $147.93, target $162.99
⚖️ Watchlist only: 1.8:1 risk/reward fails the 2:1 threshold, no imminent catalyst for a long entry.
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/NVS0624